Two Stable Chronic Conditions and a Prescription Refill: What Level Is It Really?
An established 62-year-old patient with hypertension and type 2 diabetes returns to her family physician. Both conditions are documented as stable and at goal on current therapy. The physician orders a CBC and a basic metabolic panel, renews lisinopril, and documents "45 minutes total time spent on the date of the encounter" without further breakdown. The patient also mentions a 4-mm seborrheic keratosis on her back that clothing has been irritating; the physician destroys it with electrodesiccation. The note is otherwise complete and well written. The practice submitted 99215-25 with 17110 and a prolonged-service add-on code.
1. Determine the correct E/M level using the 2021+ office/outpatient MDM framework, showing each element.
Read the worked answer
Problems: two stable chronic illnesses → low. No acute problem, no undiagnosed new problem, no exacerbation.
Data: ordering a CBC and a BMP is Category I (ordering a test) → limited. Moderate data requires three of the three Category I elements (review of prior external notes, order/review of a unique test, assessment requiring an independent historian). Only one is present.
Risk: prescription drug management (renewing lisinopril) → moderate.
Result: low, limited, moderate. The level is set by the highest level met in at least two of the three elements, and only risk reaches moderate. That supports 99213, not 99214 and certainly not 99215.
The 45 minutes does not rescue it. Time-based selection requires that the total time be documented and that the time actually reflects the encounter; time attributable to a separately reported service (the destruction) is excluded. A bare "45 minutes" with no support cannot be used to leap two levels, and pairing it with an MDM that supports 99213 creates an internal contradiction an auditor will spot immediately. 99215 plus a prolonged-service add-on here is a two-level overcode with an add-on that is only payable with 99205/99215 - a compounding error.
2. Is modifier 25 on the E/M appropriate, and how should 17110 be reported? What would make modifier 25 inappropriate?
Read the worked answer
Modifier 25 is appropriate. There is an E/M service on the same date as a minor procedure, and the E/M addressed problems distinct from the lesion - stable hypertension and diabetes requiring medication management and laboratory ordering. The physician's note independently documents the MDM for the chronic conditions.
17110 - destruction of benign lesions other than skin tags or cutaneous vascular proliferative lesions, up to 14 lesions - reported once, no modifier needed. A seborrheic keratosis is benign; if the lesion had been a skin tag, 11200 would apply instead, which is a site-and-type distinction, not a level distinction.
When 25 would fail: if the only documented work were the inspection and destruction of the keratosis. That is the procedure's own pre- and post-service work, already included in 17110's global package. Appending 25 to an E/M that exists solely to look at the lesion is a classic unbundling pattern that recovery auditors target - and with 99215 on the line, it converts an error into a credible fraud indicator.